Lexicon Pharmaceuticals Inc

Novo Nordisk and Lexicon Pharmaceuticals reached a key milestone in the development of first-in-class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The advancement of LX9851 adds a new mechanism of action to Novo Nordisk's obesity pipeline alongside its existing treatments. The update underscores ongoing efforts to address obesity as a major global health challenge with next-generation therapies.

Lexicon Pharmaceuticals has completed enrollment in its pivotal Phase 3 SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, with top-line data expected in the first quarter of 2027. The study substantially exceeded its enrollment target of 500 patients, with a substantial majority having non-obstructive HCM, a group with limited treatment options. Lexicon also reported that NDA resubmission activities for ZYNQUISTA in type 1 diabetes are nearing completion, with resubmission anticipated in the fourth quarter of 2026 based on data from the STENO1 study. Additionally, Novo Nordisk is conducting Phase 1 clinical development of LX9851 for obesity, with the program expected to complete in the first quarter of 2027. For the second quarter of 2026, Lexicon posted a net loss of $31.8 million, or $0.07 per share, compared to net income of $3.3 million, or $0.01 per share, in the prior-year period, while cash and investments stood at $190.6 million as of June 30, 2026.

The global carcinoid syndrome market is expected to record significant growth during the 2025–2035 forecast period, supported by the rising prevalence of neuroendocrine tumors, improved diagnostic capabilities and increasing demand for effective symptom management. Market expansion is also being supported by advances in targeted treatments and the availability of U.S. Food and Drug Administration-approved therapies, with somatostatin analogs, telotristat ethyl and peptide receptor radionuclide therapy remaining important components of treatment strategies. North America holds the largest share of the market, benefiting from advanced healthcare infrastructure, established neuroendocrine tumor treatment networks and broad access to approved medicines. Key drivers include the rising prevalence of neuroendocrine tumors, advancements in treatment options, greater awareness and earlier diagnosis, and increasing research investment, while high treatment costs and limited options for advanced cases remain major challenges. Prominent companies operating in the market include Novartis AG, Ipsen, Lexicon Pharmaceuticals and Crinetics Pharmaceuticals.

Lexicon Pharmaceuticals has gained more than 15% over the past month, driven by its inclusion in the Russell 3000 index and strong fiscal first quarter 2026 earnings. The company posted $21.1 million in revenue, far exceeding expectations of $9.78 million, with revenue growing 1,523% year-over-year, boosted by $20 million in development milestones from the Novo Nordisk licensing agreement for the LX9851 obesity program. Liquidity strengthened with a new $100 million loan facility from Hercules Capital, with an initial $55 million funded to support operations for at least the next 12 months. Management highlighted strong progress for the SONATA-HCM Phase 3 trial and plans to resubmit the ZYNQUISTA New Drug Application for type 1 diabetes by mid-2026. Citi raised its price target on the stock to $3.10 from $2.30 and maintained a Buy rating.

Lexicon Pharmaceuticals is advancing its cardiometabolic franchise with several potentially transformative milestones expected over the next 12 months. The company's sole marketed drug, sotagliflozin, sold as Inpefa, is being evaluated in the pivotal phase III SONATA-HCM study for hypertrophic cardiomyopathy, with top-line data anticipated in the first quarter of 2027. Lexicon is also pursuing approval of sotagliflozin for glycemic control in adults with type 1 diabetes under the brand name Zynquista, targeting an NDA resubmission and potential regulatory approval in 2026. Additionally, Novo Nordisk is developing Lexicon's obesity-focused asset LX9851 in a phase I study expected to complete in early 2027, under a licensing agreement that has already provided $55 million in upfront and milestone payments and could yield up to $1 billion in further milestones plus royalties. Another pipeline asset, pilavapadin, is advancing into phase III development for diabetic peripheral neuropathic pain and could become the first oral, non-opioid therapy approved for neuropathic pain in more than 20 years. Year to date, Lexicon shares have surged 74.8 percent against an industry decline of 1.7 percent.